Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2009-07-15 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Human trial first ten patients achieve significant milestone 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 16 July 2009 from bioMD Limited regarding a human trial update for their CardioCel biomaterial patch. It provides clinical trial results and commentary on the safety and efficacy of the product. The document is short (4055 characters) and is an announcement of clinical trial progress rather than a financial report or detailed regulatory filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not a report publication announcement since it contains substantive information about the trial results. The content fits best under a general regulatory announcement category related to clinical trial updates, which aligns with Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2009-07-15 English
Boardroom radio audio broadcast 1 page ?Kb
Investor Presentation Classification · 90% confidence The document is an announcement to the Australian Stock Exchange about an audio broadcast presentation by the Managing Director regarding a patent grant and a conference presentation. It provides a link to listen to the broadcast and details about the presentation event. The document is short (1399 characters) and does not contain any financial data, financial results, or detailed report content. It is clearly an announcement of a presentation event rather than the presentation or report itself. Therefore, it fits best under Investor Presentation (IP) as it relates to a presentation for investors or the market about company developments.
2009-07-09 English
New patent for surgical tissue replacement eng technology 1
Regulatory Filings Classification · 95% confidence The document is a short announcement from bioMD Limited to the Australian Stock Exchange regarding the granting of a new patent for their tissue engineering technology. It is dated 8 July 2009 and is only 1 page long with 2245 characters, which is quite brief. The content focuses on the patent grant and its commercial implications, with no financial data, no detailed report, or regulatory certification. It is not an annual or interim report, earnings release, or any detailed financial or management report. It is also not a voting result, board change, or legal proceeding. The document is an official announcement to the stock exchange about a patent, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document is not a report publication announcement since it does not mention any report being published or attached. Therefore, the most appropriate classification is Regulatory Filings (RNS). Confidence is high given the clear nature and content of the document.
2009-07-07 English
bioMD to attend World Heart Valve Disease Meeting 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement to the Australian Stock Exchange about company representatives attending a medical conference and presenting clinical papers. It contains no financial data, no report or filing, and is primarily a corporate event announcement. The document length is short (2995 characters), and it does not mention any financial results, regulatory filings, or report publications. It is not a report or a financial filing but a general regulatory announcement to the stock exchange about company activities. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2009-06-24 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y – Change in Director’s Interest Notice' and references Listing Rule 3.19A.1 and section 205G of the Corporations Act, which relate to director shareholding disclosures. The content details changes in a director's relevant interests in securities, including number of shares held before and after the change, nature of the change, and confirms no change to beneficial ownership. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on this disclosure, with no financial statements or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2009-06-11 English
Change in substantial holding 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a notice titled 'Change of Substantial Holder Notice' and includes a Form 604 under the Corporations Act 2001 Section 671B, which is a formal notification of changes in substantial shareholding interests. It details the previous and current voting power of a substantial shareholder, changes in relevant interests, and associated information. This type of document is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document length is 3804 characters, which is consistent with a detailed notification rather than a brief announcement or a full report. Therefore, the correct classification is MRQ with high confidence.
2009-06-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.